A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M. Oza, Daniela Matei, Lynda D. Roman et al.|Clinical Cancer Research|2019Cited by 90
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.Ursula A. Matulonis, Daniela Matei, Amit M. Oza et al.|Journal of Clinical Oncology|2016Cited by 8